Proof in the Numbers; this Psychedelic Mushroom Company is Growing its Business.
It has been just over a month since Stockhouse readers were
introduced to
Champignon Brands Inc. (CSE: SHRM, OTCQB: SHRMF, Forum) and its suite of medicinal mushroom health products. Since that time, the Company has been very busy advancing its merger and acquisition activity, as well as moves into the psychedelic segment of its market under its transformation. It is all a part of the plan, as management stated, with a lot of work accomplished in such a short amount of time.
Now gaining exposure to the immense
OTCQB Venture marketplace, Champignon can engage entrepreneurial and development stage companies in the United States and internationally, as its shares just graduated to this level of investment.
A leader in the $5.8 billion “Shroom Boom”, the human optimization sciences Company specializes in formulating its suite of
medicinal mushrooms and health products, along with novel ketamine, anesthetics, as well as adaptogenic delivery platforms for the nutritional, wellness and alternative medicine industries. Its key ingredient, psilocybin mushrooms (also known as magic or a psychedelic mushroom), is one of a polyphyletic group of fungi that contain psilocybin and psilocin. Champignon is focused on applying its novel and natural treatment protocols to address a broad range of disorders and deficiencies with an emphasis on psychedelic medicine.
Over the past few months, Champignon Brands has grown its business via securing stable psilocybin supply, under Drug Enforcement Administration (DEA) Schedule I License for traumatic brain injury and post-traumatic stress disorder (TBI / PTSD) studies at the University of Miami (UM), while also expanding its preclinical pipeline with measured psilocybin dosage studies at UM and also acquired Health Canada’s only approved psychedelic medicine clinic.
Let’s take a deeper look at these recent developments with Company….
In April 2020; Champignon advanced its clinical pipeline via a long-term supply of psilocybin for its ongoing TBI / PTSD-focused preclinical studies at the University of Miami’s Miller School of Medicine.
In
a news update for investors, the Company announced that its research partner and lead investigator, Dr. Michael Hoffer, had secured a sustainable supply of psilocybin under a DEA schedule I license, which will be used for ongoing psilocybin-based therapeutics studies. This comes from the same source that supplied both Johns Hopkins University and Yale University through their respective psilocybin research studies and trials. Final results are expected in 2021.
Dr. Hoffer commented that this supply will help make significant progress on this preclinical trial that studies the effects of an oral combination of psilocybin and cannabidiol (CBD) on mild TBI associated with PTSD.
“Since mTBI associated with PTSD is a combination disorder that affects more than 10 million individuals per year and has no proven medical treatment, our novel combination of medicines could be a breakthrough in treating these indications.”
These preclinical studies will be spearheaded by a key acquisition that Champignon made in
late March 2020 with
Tassili Life Sciences Corp. Dr. Hoffer noted that mTBI, especially concussion, is a significant cause of morbidity worldwide.
“What many do not realize is that TBI often occurs alongside PTSD. Up to 40% of people impacted by mTBI, a head injury causing a temporary change in mental status or consciousness, or TBI in general, also suffer from PTSD. This combination of mTBI and PTSD is even more common in U.S military members and presents a vast patient population to service and potentially heal with our novel therapeutics under development.”
This M&A play was intended to expand the Company’s preclinical trial pipeline, as well as its aggregation of broad intellectual property (IP) related to the development of novel psychedelics therapeutics and their delivery systems, targeting multiple pathological psychological diseases.
Another key acquisition executed by Champignon was
AltMed Capital Corp., a leading Canadian ketamine clinic operator, psychedelic medicine IP aggregator and novel drug discoverer. The acquisition further powers its advancements within the psychedelic medicine arena.
Named one of “The World’s Most Influential Scientific Minds” from 2014 to 2019 by Clarivate Analytics, the acquisition includes AltMed’s chief executive officer, Dr. Roger McIntyre, a professor of psychiatry and pharmacology at the University of Toronto and head of the Mood Disorders Psychopharmacology Unit at the University Health Network.
In addition to his academic and professional work in Chicago, New York and South Korea, Dr. McIntyre also developed Canada’s first-ever treatment centre to provide rapid onset treatments for persons with mood disorders, The Canadian Rapid Treatment Centre of Excellence. It is the only centre in the world that can demonstrate that rapid onset treatments that improve health outcomes in one to two weeks. The importance of this cannot be overstated, as it gets people back to work.
Developments with Champignon Brands Inc. continue to move at a rapid pace and this article focused specifically on its studies and M&A activity, there is still an immense suite of brands being advanced by the Company as well to take not of. Investors should keep watch on SHRM’s growth as the rest of 2020 into next year should prove to be a very interesting time for this Company.
FULL DISCLOSURE: This is a paid article produced by Stockhouse Publishing.